Arcadia Biosciences stock falls 20.21 percent on Nasdaq risks

Arcadia Biosciences stock (ISIN US0390143032) fell 20.21 percent to USD 0.34 in Nasdaq trading on September 24, 2026. The move comes as the company manages a Nasdaq equity shortfall and a planned reverse split authorization.

Nasdaq equity gap remains central

According to StockTitan, Arcadia reported stockholders' equity of USD 633,000 as of June 30, 2026, compared with Nasdaq's USD 2.5 million continued-listing requirement. The gap was USD 1.867 million, leaving equity 74.68 percent below the stated threshold.

The company received the Nasdaq notice on August 31, 2026, and has until October 15, 2026, to submit a compliance plan. Its common stock continues to trade on the Nasdaq Capital Market while the process moves forward, according to The Globe and Mail.

Losses outweigh operating progress

Arcadia's second-quarter 2026 revenue was USD 1.443 million, while net loss reached USD 6.266 million. Cash and cash equivalents stood at USD 4.178 million on June 30, 2026, and operating cash outflow was USD 319,000 for the quarter.

StockTitan reported that second-quarter revenue was USD 1.4 million and net loss attributable to common stockholders was USD 6.3 million. The figures show why the balance-sheet requirement matters more than revenue stability for the stock's near-term listing status.

Reverse split adds another variable

At the September 10, 2026 annual meeting, holders representing 52.3 percent of outstanding shares participated. Stockholders approved authorization for a reverse split between 1-for-2 and 1-for-10 by June 30, 2027, according to StockTitan.

Stock trades near yearly low

Arcadia Biosciences stock was trading at USD 0.34 on Nasdaq on September 24, 2026, at 1:02 p.m. ET. The price was USD 0.06, or 21.43 percent, above the 52-week low of USD 0.28 and below the 52-week high of USD 6.71.

More news and analyses on Arcadia Biosciences stock